It has been a mixed year for Aktis Oncology, Inc. insiders: $114.3 million bought by six people and $3.2 million sold by three, so more buying than selling overall.
NODELMAN OLEG (Director) made the biggest buy, worth around $37.4 million.
Quarter by quarter: Last full quarter: net selling by insiders. Insiders bought in 1 of the last 7 full quarters. Big money check: 114 institutions held AKTS as of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Czibere Akos | Executive Officer | Sell | 5,099 | $20.19 | $103K | SEC |
| Sep 24, 2026 | Czibere Akos | Executive Officer | Sell | 7,401 | $21.03 | $156K | SEC |
| Jul 21, 2026 | Herrmann Ken | Director | Sell | 1,350 | $24.56 | $33K | SEC |
| Jul 21, 2026 | Herrmann Ken | Director | Sell | 3,506 | $24.56 | $86K | SEC |
| Jul 20, 2026 | Herrmann Ken | Director | Sell | 3,065 | $25.21 | $77K | SEC |
| Jul 10, 2026 | Ron-Bigger Shulamit | COO | Sell | 4,200 | $28.75 | $121K | SEC |
| Jul 10, 2026 | Ron-Bigger Shulamit | COO | Sell | 30,000 | $27.94 | $838K | SEC |
| Jul 10, 2026 | Ron-Bigger Shulamit | COO | Sell | 15,800 | $27.13 | $429K | SEC |
| Jul 10, 2026 | Czibere Akos | Executive Officer | Sell | 14,800 | $27.13 | $402K | SEC |
| Jul 10, 2026 | Czibere Akos | Executive Officer | Sell | 30,829 | $27.95 | $862K | SEC |
| Jul 10, 2026 | Czibere Akos | Executive Officer | Sell | 4,371 | $28.71 | $125K | SEC |
| Jan 14, 2026 | Foley Todd | Director | Buy | 232,870 | $18.00 | $4.2M | SEC |
| Jan 14, 2026 | MPM ONCOLOGY INNOVATIONS FUND LP | 10% Owner | Buy | 1,112,777 | $18.00 | $20.0M | SEC |
| Jan 14, 2026 | GADICKE ANSBERT | 10% Owner | Buy | 1,112,777 | $18.00 | $20.0M | SEC |
| Jan 12, 2026 | VIDA VENTURES II-A, LLC | 10% Owner | Buy | 812,455 | $18.00 | $14.6M | SEC |
In the last 12 months Aktis Oncology, Inc. insiders made open-market purchases worth about $114.3 million and sales worth about $3.2 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in AKTS was filed on 2026-09-24.
114 investment managers reported holding AKTS in SEC Form 13F filings for Q2 2026.
No congressional trades in AKTS were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).